Crispr-cas systems and genome editing: beginning the era of crispr/cas therapies for humans

HIGHLIGHTS

• Who: Dmitry S. Karpov from the Center for Precision have published the Article: CRISPR-Cas Systems and Genome Editing: Beginning the Era of CRISPR/Cas Therapies for Humans, in the Journal: (JOURNAL)

SUMMARY

Since Cas9 from Streptococcus pyogens is the most active genome editor both in_vitro and in_vivo, smaller Cas9 orthologs are preferred. AnoCas9 from the thermophilic bacterium Anoxybacillus flavithermus, characterized in_vitro by Matveeva et_al, provides a good example of such small Cas effectors. AnoCas9 is a 1087 aa protein that exhibits nuclease activity in the 37-60 ◦ C range and a PAM . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.